TECX — Tectonic Therapeutic, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1681087 ·
Last close
$29.99
Market Cap
$565.89M
52W High
$36.03
52W Low
$21.70
ADV30
235,756
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,301,000 | -25,241,000 | 246,577,000 | 236,894,000 | 16,160,000 |
| Dec 2025 | 0 | — | -21,516,000 | -19,226,000 | 261,038,000 | 253,798,000 | 9,709,000 |
| Sep 2025 | 0 | — | -21,890,000 | -19,035,000 | 277,001,000 | 268,435,000 | 9,473,000 |
| Jun 2025 | 0 | — | -22,332,000 | -19,984,000 | 295,313,000 | 287,381,000 | 11,547,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-60,078,000
Investing CF
$-138,000
Financing CF
$173,355,000
CapEx
$-211,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.05
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-222,737,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-72,858,000
Pretax Income TTM
$-72,921,000
Interest Exp TTM
$63,000
Analysts
9
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,036,000 | -74,151,000 | 261,038,000 | 9,709,000 | — | -60,078,000 |
| Dec 2024 | 0 | -58,015,000 | -57,982,000 | 152,905,000 | 12,129,000 | — | -59,080,000 |
| Dec 2023 | 0 | -44,648,000 | -42,823,000 | 39,399,000 | 124,035,000 | — | -40,681,000 |
| Dec 2022 | 0 | -32,830,000 | -32,180,000 | 47,209,000 | 92,863,000 | — | -27,637,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VALN | Valneva SE | $573.68M | $6.05 | — |
| CADL | Candel Therapeutics, Inc. | $582.50M | $7.95 | — |
| AGMB | Agomab Therapeutics NV | $544.19M | $11.05 | — |
| PRME | Prime Medicine, Inc. | $536.43M | $2.97 | — |
| EIKN | Eikon Therapeutics, Inc. | $535.97M | $9.90 | — |
News headlines (Yahoo Finance, 1h cache)
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-07 20:01 · Yahoo
Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans
2026-05-01 14:24 · Yahoo
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
2026-04-23 20:01 · Yahoo
TD Asset Management Inc. Announces TD ETF Distributions
2026-03-19 14:00 · Yahoo
Tectonic Therapeutic to Participate in March Investor Conferences
2026-03-02 13:00 · Yahoo
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
2026-02-26 21:17 · Yahoo
Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing Begins
2026-02-25 09:18 · Yahoo
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
2026-02-23 21:01 · Yahoo
Daniel Lochner Bought 70% More Shares In Tectonic Therapeutic
2026-02-14 12:00 · Yahoo
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
2026-02-11 21:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.